Inmagene LLC presented preclinical data for the novel noncovalent reversible Bruton tyrosine kinase (BTK) inhibitor IMG-004, which is in phase I development for autoimmune diseases. IMG-004 ...

During a Case-Based Roundtable® event, Andrew H. Lipsky, MD, moderated a discussion on the efficacy and safety of newer BTK ...

Nurix Therapeutics has reported positive clinical data from its ongoing Phase Ia/Ib trial of NX-5948 for Waldenstrom's ...

Furthest ahead in the pipeline is tolebrutinib, developed by Paris-based Sanofi to potentially treat SPMS, PPMS and relapsing forms of MS. The investigational agent is an oral central nervous system ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Nurix Therapeutics Inc. (NRIX) presented positive clinical data from its ongoing Phase 1a/1b clinical trial of NX-5948, an orally ...

Roche has made its case for BTK inhibitor fenebrutinib as a potential new oral therapy for multiple sclerosis, with a phase 2 readout that it says shows significant improvements in disease ...

A comparison of the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to the first-generation ibrutinib ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Exscientia plc (Nasdaq: EXAI) today announced three abstracts to be presented at the 36th EORTC-NCI-AACR (ENA) Symposium 2024 ...

Title:Clinical Activity of NX-5948 in CLL & NHL: A First-in-Class BTK Degrader Presenting author: Paula G. O’Connor, M.D., ...